Prism Medico & Pharmacy Limited has confirmed to stock exchanges that its corporate website is updated and operational, ensuring adherence to regulatory disclosure norms. The company notified the Bombay Stock Exchange (BSE) and the Metropolitan Stock Exchange of India Limited (MSEI) on July 30, 2026, stating that the platform meets the requirements of Regulation 46 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. This update guarantees that investors and stakeholders have continuous access to mandatory information hosted on the company’s digital infrastructure. The move reinforces the firm's commitment to transparency and timely dissemination of material information to the market.

The notification was issued by Davender Singh, Director of Prism Medico & Pharmacy Limited, carrying DIN 09447213. The communication was directed to the Department of Corporate Services at BSE Limited in Mumbai and the Listing Department at MSEI in Mumbai. The company provided the specific web address https://www.prismmedico.in for record-keeping purposes and requested both exchanges to acknowledge receipt of the undertaking.

Regulation 46 mandates listed entities to maintain a dedicated section on their websites for publishing all disclosures required under the SEBI LODR Regulations. By certifying that the website is functional, Prism Medico & Pharmacy Limited affirms that it has no technical barriers preventing investors from accessing annual reports, financial results, board meeting notices, or other statutory filings. This compliance step is routine but critical for maintaining listing status and avoiding regulatory scrutiny regarding information accessibility.

Compliance Details

The following table outlines the key details of the regulatory communication submitted by the company:

Regulatory Context

SEBI’s Listing Obligations and Disclosure Requirements emphasize the importance of digital accessibility for investor protection. Regulation 46 specifically requires listed companies to publish all disclosures on their websites within prescribed timelines. A non-functional or outdated website can lead to penalties or adverse remarks from regulators during inspections. By proactively informing the exchanges, Prism Medico & Pharmacy Limited demonstrates adherence to these governance standards. The company’s registered office is located at Suketi Road, Kala Amb, Sirmaur, Himachal Pradesh-173030.

Prism Medico and Pharmacy Limited reported a net profit of ₹31.84 lakh for the financial year ended March 31, 2026, reversing the net loss of ₹4.87 lakh recorded in the previous year. Revenue from operations surged to ₹244.34 lakh in FY26 from ₹63.19 lakh in FY25, driven primarily by the sale of pharmaceutical products. The board approved the audited standalone financial results at its meeting held on May 28, 2026, at the registered office in Kala Amb, Himachal Pradesh.

Financial Performance

The company’s total income for FY26 stood at ₹246.95 lakh, a significant increase from ₹64.84 lakh in the previous year. Total expenses for the period were ₹203.99 lakh, up from ₹71.42 lakh in FY25. The profit before tax for the year was ₹42.96 lakh, compared to a loss before tax of ₹6.58 lakh in the preceding year. The board reviewed the performance for the quarter and financial year ended March 31, 2026, along with the Auditors Report.

Auditor and Compliance Details

The statutory auditors, Garg Mendiratta & Associates, issued an unmodified opinion on the financial statements. The audit report confirms that the company has not incurred any cash losses in the current financial year, compared to a cash loss of ₹6.16 lakh in the preceding year. The board also approved the recommendation of a dividend, if any, subject to the approval of shareholders. The disclosure was made in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.